

AMCAL AND GUARDIAN CORE RANGE MUTE AUSTRALIA WIDE

Highlights:

- Mute added to national core range in Amcal and Guardian Pharmacies
- All 4 Mute products (Trial Pack, Small, Medium, Large) to be ranged on shelf
- Sigma has now opened access to Mute to its entire distribution network over 4000 pharmacies
- Significantly increases Mute's Australian retail footprint

May 8th, 2017. Melbourne, Australia.

Respiratory technology company Rhinomed (ASX:RNO) is pleased to announce that it has been advised by Sigma Healthcare that Mute sleep technology will form part of the 2017 core range for the Amcal and Guardian pharmacy brands. This adds to Rhinomed's existing Sigma relationship which saw Discount Drug Stores stock Mute, meaning the majority of Sigma Healthcare's branded network of over 700 pharmacies now core range Mute.

In addition, Sigma has also notified the company that the Mute product suite is now available for order by over 4000 pharmacies in its distribution network.

The core ranging means all 4 Mute products (trial pack, small, medium and large) will be available in Amcal and Guardian stores Australia wide. An initial order is expected shortly. The expanded access by Sigma Healthcare allows every pharmacy within the Sigma network to range Mute.

Mute will be supplied to Sigma by The Linde Group's Australian subsidiary BOC Ltd, as part of the agreement disclosed to the ASX in December 2016. This latest deal, combined with the other recent announcements means Mute is now ranged in a significant number of Australian pharmacies. The company believes this is a giant step in ensuring that Mute can become Australia's premier, front line solution for snoring and nasal congestion.

Mute is an over-the-counter product that supports nasal breathing, enabling snorers or those with nasal obstruction and congestion to breathe more easily through their nose and help keep their mouth closed during sleep. Mute is designed to fit the natural anatomy of the nose and is individually adjustable on both sides so you can control the level of dilation and airflow.

Media Enquiries

Michael Johnson, CEO & Managing Director

RHINOMED LIMITED
ABN 12 107 903 159
WWW.RHINOMED.GLOBAL

LEVEL 1, 4-10 AMSTERDAM STREET, RICHMOND 3121

TEL: +61 (0) 3 8416 0900 FAX: +61 (0) 3 8080 0796



+61 (03) 8416 0900 mjohnson@rhinomed.global

Follow us on

Twitter @rhinomedceo and @mutesnoring

About Rhinomed Limited (ASX:RNO)

Rhinomed Limited is a Melbourne, Australia based technology firm with a focus on nasal, respiratory and breathing management technologies. The company is developing and commercialising applications of its technology portfolio in the sport, sleep, cough/cold and allergy, and drug delivery markets. The company has two products in market (the Turbine for sports and exercise and Mute for snoring and better sleep) and has recently completed a pilot Phase I clinical trial of its new INPEAP technology targeting mild to moderate sleep apnea. For more information, go to www.rhinomed.global.

About Mute™

Mute™ is a unique nasal respiratory technology that has been found to reduce the volume and frequency of snoring in 75% of users*. Mute is easy to use, drug free and fits discreetly inside the nose. Made from ultra-soft polymers, Mute gently expands each nostril to increase the volume of air in each breath. By doing so, Mute encourages nasal breathing and reduces the need to open the mouth during sleep, factors critical to a reduction in snoring and better sleep. For more information or to purchase online, visit www.mutesnoring.com

*Mute in-home user trial, 2014. n=118 couples.

TEL: +61 (0) 3 8416 0900 FAX: +61 (0) 3 8080 0796